- Home
- » Tags
- » Surrogate endpoint
Top View
- Time to Review the Role of Surrogate Endpoints in Health Policy: State of the Art and the Way Forward
- Of Adaptive Design Clinical Trials for Drugs and Biologics Guidance
- Considerations for the Use of Biomarkers in the Study of Rare Diseases
- (Radiation) Therapy
- Endpoints in Vaccine Trials
- Surrogate Endpoints in Oncology Clinical Trials: Are We There Yet? from a Practical Perspective
- Review of Meta-Analyses Evaluating Surrogate Endpoints for Overall Survival in Oncology
- Assay Validation and Reproducibility Considerations for Biomarkers Used in Drug Development
- FDA Briefing Document Developing Antibacterial Therapies Targeting A
- Endpoint Surrogacy in Oncology Phase 3 Randomised Controlled Trials
- Outcomes, Surrogates, Composite Endpoints (Day)
- Usage of Surrogate Endpoints in the Design and Analysis of Clinical Trials
- Predictive Probability of Success Using Surrogate Endpoints
- Innovative Clinical Study Design for Gene and Cell Therapies Jake Elkins, MD Head, Clinical Sciences Sarepta Therapeutics Problem Statement
- A Randomised Controlled Trial Is Not a Pilot Trial Simply Because It Uses a Surrogate Endpoint
- Developing Antiretroviral Drugs for Treatment Guidance for Industry
- Mechanistic Evidence in Evidence-Based Medicine: a Conceptual Framework
- Validation of Surrogate Endpoints for Clinical Trials
- Evaluating a Surrogate Endpoint at Three Levels, with Application to Vaccine Development
- Considerations for Discussion of a New Surrogate Endpoint(S) at a Type C PDUFA Meeting Request
- The Roles of Short Term Endpoints in Clinical Trial Planning and Design
- Converting a Biomarker to a Surrogate What Should It Take? Astrazeneca Priority List- Case Studies
- How Could We Enhance Translation of Sepsis Immunology to Inform Immunomodulation Trials in Sepsis? M
- WHO Preferred Product Characteristics for Group B Streptococcus Vaccines
- SURROGATE OUTCOME MEASURES USED in CRITICAL CARE TRIALS Systematic Review Protocol
- Reg Ebola Vaccines
- Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Guidance for Industry
- Endpoint Refinement for Total Body Irradiation of C57BL/6 Mice
- Role of Surrogates in Clinical Trials
- FDA Survey to Identify Potential Biomarkers for Qualification
- Surrogate Endpoints.Pdf
- Clinical Endpoints and Adaptive Clinical Trials in Precirrhotic Nonalcoholic Steatohepatitis: Facilitating Development Approaches for an Emerging Epidemic
- An R Package for the Evaluation of Failure Time Surrogate Endpoints in Individual Patient Data Meta-Analyses of Randomized Clinical Trials
- Body Temperature and Mouse Scoring Systems As Surrogate Markers of Death in Cecal Ligation and Puncture Sepsis Safiah H
- An Initial Evaluation of a Surrogate Endpoint Using a Single Randomized Clinical Trial and the Prentice Criteria
- Binary Surrogate Endpoints in Clinical Trials from the Perspective of Case Definitions
- Definitions and Validation Criteria for Biomarkers and Surrogate Endpoints: Development and Testing of a Quantitative Hierarchical Levels of Evidence Schema
- Clinical Trials to Assess Adjuvant Therapeutics for Severe Malaria Rosauro Varo1,2†, Clara Erice3†, Sydney Johnson4, Quique Bassat1,2,5,6,7† and Kevin C